Tech Company Financing Transactions

Vivaldi BioSciences Funding Round

Vivaldi BioSciences, based in Fort Collins, received $2 million from Bay City Capital, NGN Capital and private investors.

Transaction Overview

Announced On
9/30/2010
Transaction Type
Venture Equity
Amount
$1,975,200
Round
Undisclosed
Investors

Bay City Capital (William Gerber)

NGN Capital (Peter Johann)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3185-A Rampart Rd. 0922
Fort Collins, CO 80523
USA
Email Address
Overview
Vivaldi Biosciences Inc. is developing genetically engineered vaccines with the potential for increased effectiveness in the prevention of common seasonal influenza ("flu") and emergent pandemic flu.
Profile
Vivaldi BioSciences LinkedIn Company Profile
Social Media
Vivaldi BioSciences Company Twitter Account
Company News
Vivaldi BioSciences News
Facebook
Vivaldi BioSciences on Facebook
YouTube
Vivaldi BioSciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
William Wick
  William Wick LinkedIn Profile  William Wick Twitter Account  William Wick News  William Wick on Facebook
Chief Scientific Officer
Thomas Muster
  Thomas Muster LinkedIn Profile  Thomas Muster Twitter Account  Thomas Muster News  Thomas Muster on Facebook
VP - Manufacturing
Manfred Reiter
  Manfred Reiter LinkedIn Profile  Manfred Reiter Twitter Account  Manfred Reiter News  Manfred Reiter on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/30/2010: Radiate Media venture capital transaction
Next: 9/30/2010: BirdDog Solutions venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary